HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Novel coronavirus infection (COVID-19): epidemiology, clinical characteristics of patients, risk of complications, prevention, use of selenium-containing drugs

DOI: https://doi.org/10.29296/25877305-2022-05-12
Issue: 
5
Year: 
2022

Professor D. Dedov, MD
Tver State Medical University
Tver Regional Clinical Cardiology Dispensary

The article presents an analysis of Russian and foreign publications. The authors reflected the epidemiology, clinical characteristics of patients and risk of complications in patients with novel coronavirus infection (COVID-19). They noted correlations of selenium (Se) deficiency and severity of the course of the said disease. Se deficiency was associated with oxidative stress, hyperinflammation, complications of COVID-19. Showed the need for sufficient serum Se for proper functioning of the immune, reproductive systems, thyroid gland, brain. Recognized that the organic form of Se (selenocystin) had high bioavailability. Concluded that the severity of the course of COVID-19, along with other risk factors, may be related to the low serum Se content of patients. Additional prescription of selenium-containing drugs requires an individual approach, considering the data of complex clinical and instrumental examination, comorbid diseases existing in patients. Administration of SELENBIO for women may be recommended for complex prophylaxis of COVID-19, increasing of body adaptation potential and maintenance of healthy immune system.

Keywords: 
novel coronavirus infection
epidemiology
clinical characteristics
patients
complications
selenium-containing drugs
SELENBIO for women
selenocysteine
Astragalus dasyanthus Pall



References: 
  1. Avdeev S.N., Adamyan L.V., Alexeeva E.I. et al. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19): Provisional guidelines. M.: Ministry of Health of the Russian Federation, 2021; 233 p. (in Russ.).
  2. Livzan M.A., Drapkina O.M., Nikolaev N.A. et al. Algorithms for adult outpatient care of coronavirus disease 2019 (COVID-19) and its Assumption. Cardiovascular Therapy and Prevention. 2021; 20 (4): 2916 (in Russ.). DOI: 10.15829/1728-8800-2021-2916
  3. Glybochko P., Fomin V., Avdeev S, et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020; 29 (2): 21–9 (in Russ.). DOI 10.32756/0869-5490-2020-2-21-29
  4. Zabolotskikh I.B., Kirov M.Yu., Lebedinskii K.M., et al. Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. 2022; 1: 5–140 (in Russ.). DOI: 10.21320/1818-474X-2022-1-5-140
  5. Palakshappa J.A., Krall J.T.W., Belfield L.T. et al. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation. Crit Care Clin. 2021; 37 (4): 895–911. DOI: 10.1016/j.ccc.2021.05.010
  6. Glybochko P.V., Fomin V.V., Moiseev S.V. et al. Risk factors for the early development of septic shock in patients with severe COVID-19. Terapevticheskii arkhiv. 2020; 92 (11): 17–23 (in Russ.). DOI: 10.26442/00403660.2020.11.000780
  7. Khirmanov VN. COVID-19 as a systemic disease. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2021; 30 (1): 5–15 (in Russ.). DOI: 10.32756/0869-5490-2021-1-5-15
  8. Starshinova A.A., Kushnareva E.A., Kudlay D.A. et al. Prospects for a COVID-19 treatment: review. Translational Medicine. 2020; 7 (3): 30–7 (in Russ.). DOI: 10.18705/2311-4495-2020-7-3-30-37
  9. Bermano G., Méplan C., Mercer D.K. et al. Selenium and viral infection: are there lessons for COVID-19? Br J Nutr. 2021; 125 (6): 618–27. DOI: 10.1017/S0007114520003128
  10. Khatiwada S., Subedi A. A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19). Curr Nutr Rep. 2021; 10 (2): 125–36. DOI: 10.1007/s13668-021-00354-4
  11. Zhang H.Y., Zhang A.R., Lu Q.B. et al. Association between fatality rate of COVID-19 and selenium deficiency in China. BMC Infect Dis. 2021; 21 (1): 452. DOI: 10.1186/s12879-021-06167-8
  12. Younesian O., Khodabakhshi B., Abdolahi N. et al. Decreased Serum Selenium Levels of COVID-19 Patients in Comparison with Healthy Individuals. Biol Trace Elem Res. 2022; 200 (4): 1562–7. DOI: 10.1007/s12011-021-02797-w
  13. Liu Q., Zhao X., Ma J. et al. Selenium (Se) plays a key role in the biological effects of some viruses: Implications for COVID-19. Environ Res. 2021; 196: 110984. DOI: 10.1016/j.envres.2021.110984
  14. Moghaddam A., Heller R.A., Sun Q. et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. Nutrients. 2020; 12 (7): 2098. DOI: 10.3390/nu12072098
  15. Hossain A., Skalicky M., Brestic M. et al. Selenium Biofortification: Roles, Mechanisms, Responses and Prospects. Molecules. 2021; 26 (4): 881. DOI: 10.3390/molecules26040881
  16. Okladnikova E.V., Potupchik T.V., Evert L.S. et al. Features of metabolism and spectrum of action of selenium, possibilities of application of selene-containing food supplements under SARS-CoV-2 pandemic conditions. Problems of Biological, Medical and Pharmaceutical Chemistry. 2022; 25(3): 23–33 (in Russ.). DOI: 10.29296/25877313-2022-03-04
  17. Poluboyarinov P.A. Biofortification of Astragalus astragalus woolly-flowered (Astragalus dasyanthus Pall.) plants with the amino acid L-selenocysteine. Problems of Biological, Medical and Pharmaceutical Chemistry. 2019; 22 (12): 64 (in Russ.). URL: https://www.secret-dolgolet.ru/biofortifikatsiya-rasteniy-astragala-sherstistotsvetkovogo-astragalus-dasyanthus-pall-aminokislotoy-l-selenotsistinom/
  18. Poluboyarinov P.A., Elistratov D.G., Shvets V.I. Metabolism and mechanism of toxicity of selenium-containing supplements used for optimizing human selenium status. Fine Chemical Technologies. 2019; 14 (1): 5–24 (in Russ.). DOI: 10.32362/2410-6593-2019-14-1-5-24
  19. Dedov D.V., Marchenko S.D. Vitamins, iron, zinc, selenium, selenium-containing drugs in the complex prevention of complications and treatment of patients with COVID-19. Pharmacy. 2022; 71 (1): 5–9 (in Russ.). DOI: 10.29296/25419218-2022-01-01
  20. Potupchik T., Okladnikova E., Dresvyanskaya T. Prevention of obesity and scleropolycystis with the use of dietary supplement SELENBIO for women. Vrach. 2022; 33 (3): 35–42 (in Russ.). DOI: 10.29296/25877305-2022-03-07
  21. Elistratov D.G. Osteo-Vit D3 and Selenbio for women in the prevention of COVID-19 and postvoid complications. Meditsinskaya sestra. 2022; 24 (2): 42–8 (in Russ.). DOI: 10.29296/25879979-2022-02-10